Sun Pharma to Acquire 100% Stake in Antibe Therapeutics: Expanding Global Reach

Sun Pharmaceutical Industries, one of the largest pharmaceutical companies in India, announced its decision to acquire a 100% stake in Antibe Therapeutics, a Canadian-based biotechnology company specializing in pain and inflammation solutions. This acquisition marks a strategic move for Sun Pharma to strengthen its presence in the global pharmaceutical and biotechnology markets.Antibe’s proprietary hydrogen sulfide-releasing platform has been recognized for developing next-generation therapies for inflammatory pain, a market with significant growth potential. This acquisition aligns with Sun Pharma's mission to expand its innovative product portfolio and tap into advanced therapeutic solutions.The deal is subject to customary regulatory approvals and is expected to bolster Sun Pharma’s research and development capabilities in chronic pain and inflammation management.

Source: Official company announcements and market reports.